Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
The Oncologist
|
October 9, 2015
Hope Is Palliative
Julie Byrne, Michael Byrne
The Journal of IMA
|
April 24, 2013
Compassionate care
Stephen G Post, Julie Byrne
BMJ Open Quality
|
May 3, 2018
Reducing the rate of post-surgical urinary tract infections in orthopedic patients
Amit Thakker, Natasha Briggs, Azusa Maeda, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Pharmacogenomics
|
August 13, 2015
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms
Laura R Parham, Linda P Briley, Karen S King, et al.
Work (Reading, Mass.)
|
September 19, 2017
Parental awareness of schoolbag carriage: A comparative study of Irish and United States parents
Sara Dockrell, Karen Jacobs, Julie Byrne, et al.
Breast Cancer Research and Treatment
|
January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P Crown, Harold A Burris, Fran Boyle, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Ophthalmology and Therapy
|
July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Ophthalmology and Therapy
|
September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
The Oncologist
|
October 9, 2015
Hope Is Palliative
Julie Byrne, Michael Byrne
The Journal of IMA
|
April 24, 2013
Compassionate care
Stephen G Post, Julie Byrne
BMJ Open Quality
|
May 3, 2018
Reducing the rate of post-surgical urinary tract infections in orthopedic patients
Amit Thakker, Natasha Briggs, Azusa Maeda, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Pharmacogenomics
|
August 13, 2015
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms
Laura R Parham, Linda P Briley, Karen S King, et al.
Work (Reading, Mass.)
|
September 19, 2017
Parental awareness of schoolbag carriage: A comparative study of Irish and United States parents
Sara Dockrell, Karen Jacobs, Julie Byrne, et al.
Breast Cancer Research and Treatment
|
January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P Crown, Harold A Burris, Fran Boyle, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Ophthalmology and Therapy
|
July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Ophthalmology and Therapy
|
September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Page
of 2